GLK-321 low dose BID + GLK-321 mid dose BID + GLK-321 high dose BID + GLK-321 high dose QD + Placebo BID
Phase 2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Demodex Blepharitis
Conditions
Demodex Blepharitis
Trial Timeline
Dec 5, 2025 → Nov 1, 2026
NCT ID
NCT07400965About GLK-321 low dose BID + GLK-321 mid dose BID + GLK-321 high dose BID + GLK-321 high dose QD + Placebo BID
GLK-321 low dose BID + GLK-321 mid dose BID + GLK-321 high dose BID + GLK-321 high dose QD + Placebo BID is a phase 2 stage product being developed by Glaukos for Demodex Blepharitis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07400965. Target conditions include Demodex Blepharitis.
What happened to similar drugs?
1 of 1 similar drugs in Demodex Blepharitis were approved
Approved (1) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
12
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07400965 | Phase 2 | Recruiting |
Competing Products
1 competing product in Demodex Blepharitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lotilaner ophthalmic solution, 0.25% + Vehicle control | Tarsus Pharmaceuticals | Approved | 37 |